HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo tested for advanced cancers: hope for lymphoma and solid tumors
Disease control TerminatedThis early-phase study tested a new experimental drug, PF-08046032, alone or combined with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 03:19 UTC
-
Head and neck cancer drug combo study halted early
Disease control TerminatedThis study tested a new drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The trial was stopped early, so results are limi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Experimental cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer that no longer responds to hormone therapy, as well as other solid tumors like melanoma and lung cancer. The goal was to see if the drug could shrink tumors or slow dis…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a new drug, HFB301001, in 31 adults with advanced cancers like sarcoma and melanoma. The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Immunotherapy plus radiation trial for head and neck cancer halted early
Disease control TerminatedThis study tested whether adding radiation to the immunotherapy drug pembrolizumab could help control metastatic head and neck cancer that had already been treated once. It was designed for adults with at least two tumors, one of which would receive radiation. The trial was termi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
Experimental combo therapy trial halted early
Disease control TerminatedThis early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated, so result…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Tiny trial tests smarter chemo delivery in head and neck cancer
Knowledge-focused TerminatedThis early-phase study tested a new version of the chemotherapy drug paclitaxel, called FID-007, in people with head and neck cancer. The goal was to see how the drug affects immune cells around the tumor. Only one person took part before the study was stopped early.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated May 26, 2026 03:20 UTC